Chromatin Bioscience Enters Collaboration Agreement with Astellas
Tuesday, April 15, 2025
Chromatin Bioscience, known for its work in developing synthetic promoters and gene control systems, has entered into a collaboration agreement with Astellas Pharma, a global company in the life sciences sector.
As part of the agreement, Chromatin Bioscience will apply its proprietary chromatinLENS platform to create cell-selective synthetic promoters that meet Astellas’ specific requirements. These promoters are expected to support accurate and long-lasting gene expression in targeted cell types.
The chromatinLENS platform allows for the discovery of gene regulatory elements from lesser-known regions of the genome. It also supports the design of synthetic promoters for use in various sectors, including therapeutics, agritech, industrial biotechnology, and bioprocessing.
This agreement highlights the growing interest in synthetic promoter technology and supports Chromatin Bioscience’s continued development and expansion. It also marks another step in the company's series of strategic partnerships.
Source: prnewswire.com
